Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

被引：36
作者：
Hanauer, Stephen B. [1 ]
机构：
[1] Univ Chicago Hosp, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA
来源：
GUT | 2007年 / 56卷 / 09期
关键词：
D O I：
10.1136/gut.2006.115980
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.
引用
收藏
页码：1181 / 1183
页数：3
相关论文
共 45 条
[1]   Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles [J].
Anderson, PJ .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) :19-22
[2]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[3]   Predictors of Crohn's disease [J].
Beaugerie, L ;
Seksik, P ;
Nion-Larmurier, I ;
Gendre, JP ;
Cosnes, J .
GASTROENTEROLOGY, 2006, 130 (03) :650-656
[4]  
Cohen RD, 2000, AM J GASTROENTEROL, V95, P3469
[5]   Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Enns, Robert ;
Hanauer, Stephen B. ;
Panaccione, Remo ;
Schreiber, Stefan ;
Byczkowski, Dan ;
Li, Ju ;
Kent, Jeffrey D. ;
Pollack, Paul F. .
GASTROENTEROLOGY, 2007, 132 (01) :52-65
[6]   Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease [J].
Corken Mackey, Ann ;
Green, Lanh ;
Liang, Li-ching ;
Dinndorf, Patricia ;
Avigan, Mark .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 44 (02) :265-267
[7]  
D'Haens GR, 2006, GASTROENTEROLOGY, V130, pA110
[8]   Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine [J].
Dayharsh, GA ;
Loftus, EV ;
Sandborn, WJ ;
Tremaine, WJ ;
Zinsmeister, AR ;
Witzig, TE ;
Macon, WR ;
Burgart, LJ .
GASTROENTEROLOGY, 2002, 122 (01) :72-77
[9]   Review article: thiopurines in inflammatory bowel disease [J].
Derijks, L. J. J. ;
Gilissen, L. P. L. ;
Hooymans, P. M. ;
Hommes, D. W. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (05) :715-729
[10]   Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics [J].
Ekstrom Smedby, Karin ;
Baecklund, Eva ;
Askling, Johan .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (11) :2069-2077
12345